Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration - PubMed (original) (raw)
Multicenter Study
. 2013 Jul;156(1):29-35.e2.
doi: 10.1016/j.ajo.2013.03.030. Epub 2013 May 10.
Affiliations
- PMID: 23668679
- DOI: 10.1016/j.ajo.2013.03.030
Multicenter Study
Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration
Yoshihiro Yonekawa et al. Am J Ophthalmol. 2013 Jul.
Abstract
Purpose: To explore the visual and anatomic outcomes of patients with refractory or recurrent neovascular age-related macular degeneration (AMD) who were converted from bevacizumab and/or ranibizumab to aflibercept.
Design: Two-center, retrospective chart review.
Methods: Treatment history, visual acuity (VA), and central macular thickness (CMT) on spectral-domain optical coherence tomography were collected. Patients were divided into "refractory" (persistent exudation despite monthly injections) or "recurrent" (exudation suppressed, but requiring frequent injections).
Results: One hundred and two eyes of 94 patients were included; 68 were refractory and 34 were recurrent. Eyes received a mean of 20.4 prior bevacizumab/ranibizumab injections and a mean of 3.8 aflibercept injections. Mean follow-up was 18 weeks. Mean VA was 20/50-1 before conversion, 20/50-2 after 1 aflibercept injection (P = .723), and 20/50+2 after the final injection (P = .253). Subgroup analysis of refractory and recurrent cases also showed stable VA. Of the refractory cases, mean CMT had improved after 1 injection (P < .001) and the final injection (P < .001). Intraretinal (P < .001) and subretinal (P < .001) fluid decreased after 1 injection, and the mean injection interval was extended from 5.2 to 6.2 weeks (P = .003). Of the recurrent cases, mean CMT improved after 1 injection (P < .001) and the final injection (P < .001). Intraretinal (P = .003) and subretinal (P = .046) fluid decreased after 1 injection, and the mean injection interval was extended from 7.2 to 9.5 weeks (P = .001).
Conclusions: Converting patients with chronic neovascular AMD to aflibercept results in stabilized vision and improved anatomic outcomes, while allowing injection intervals to be extended.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
- Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB. Bakall B, et al. Am J Ophthalmol. 2013 Jul;156(1):15-22.e1. doi: 10.1016/j.ajo.2013.02.017. Epub 2013 May 22. Am J Ophthalmol. 2013. PMID: 23706500 - Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
Cho H, Shah CP, Weber M, Heier JS. Cho H, et al. Br J Ophthalmol. 2013 Aug;97(8):1032-5. doi: 10.1136/bjophthalmol-2013-303344. Epub 2013 Jun 13. Br J Ophthalmol. 2013. PMID: 23766432 - SAVING SIGHT IN NEOVASCULAR AMD.
[No authors listed] [No authors listed] Retina. 2020 Jul;40 Suppl 2:S1-S12. doi: 10.1097/01.iae.0000681812.63712.10. Retina. 2020. PMID: 32558673 Review. No abstract available. - Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.
Lazzeri S, Ripandelli G, Sartini MS, Parravano M, Varano M, Nardi M, Di Desidero T, Orlandi P, Bocci G. Lazzeri S, et al. Angiogenesis. 2015 Oct;18(4):397-432. doi: 10.1007/s10456-015-9483-4. Epub 2015 Sep 7. Angiogenesis. 2015. PMID: 26346237 Review.
Cited by
- The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab.
Unsal E, Cubuk MO. Unsal E, et al. J Curr Ophthalmol. 2018 Aug 9;30(4):337-342. doi: 10.1016/j.joco.2018.07.002. eCollection 2018 Dec. J Curr Ophthalmol. 2018. PMID: 30555967 Free PMC article. - Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting.
Lüke JN, Alquoqa H, Alsamman A, Aljabary B, Schaub F, Heindl LM. Lüke JN, et al. Int Ophthalmol. 2023 Jan;43(1):13-25. doi: 10.1007/s10792-022-02383-6. Epub 2022 Jul 4. Int Ophthalmol. 2023. PMID: 35781595 Free PMC article. - Outcomes of Abrupt Switch to Bevacizumab of Patients Undergoing Aflibercept Intravitreal Injections for Neovascular Age-Related Macular Degeneration in a Tertiary Center in Lombardy, Italy: A Real-Life Retrospective Analysis.
Randazzo A, Raimondi R, Fossati G, Romano M, Sorrentino T, Castellani C, Rossi C, Cancian G, Vinciguerra P. Randazzo A, et al. J Ophthalmol. 2021 Sep 11;2021:7940297. doi: 10.1155/2021/7940297. eCollection 2021. J Ophthalmol. 2021. PMID: 34676113 Free PMC article. - Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.
Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M. Gharbiya M, et al. Biomed Res Int. 2014;2014:273754. doi: 10.1155/2014/273754. Epub 2014 May 7. Biomed Res Int. 2014. PMID: 24895562 Free PMC article. - Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT).
Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, Toth CA, Huang J, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Ying GS, et al. Ophthalmology. 2015 Dec;122(12):2523-31.e1. doi: 10.1016/j.ophtha.2015.08.015. Epub 2015 Sep 15. Ophthalmology. 2015. PMID: 26383996 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources